1 International Conference on Emerging Infectious Diseases 2000, Emerging Infect.Dis. 2000, 7: 492-594 (http://www.cdc.gov/ncidod/eid/vol7no3_supp/contents.htm), accessed 12 January 12 2002.

2 Multiple drug resistance can have different meanings, depending on the clinical indication. For tuberculosis, the definition is specific in that MDR-TB means resistance to at least isoniazid and rifampicin (Gupta R. Kim JY. Espinal MA. Caudron J-M. Pecoul B. Farmer PE. Raviglione MC. Responsding to Market Failire in Tuberculosis Control Science, 2001; 293: 1049-1051)..

3 Acar JF. Kaplan EL. O’Brien TF. Nature of the Resistance Problem, in “Monitoring and Management of Bacterial Resistance to antimicrobial agents: A World Health Organization Symposium, Clin. Infect. Dis. 1997; 24 (Supplement 1): S1.

4 World Health Organization Containing Antimicrobial Resistance: Review of the literature and Report of a WHO Workshop on the developement of a Global Strategy for the containment of antimicrobial resistance Geneva, Switzerland, 1999, WHO/CDS/CSR/DRS99.2 (http://www.who.int/emc-documents/antimicrobial_resistance/whocdscsrdrs992c.html) accessed 2 January 2002.

5 Avorn JL., Barrett. JF., Davey PG., McEwen SA., O’Brien TF., Levy SB. Antibiotic Resistance: Synthesis of recommendations by expert policy groups World Health Organization 2001, WHO/CDS/CSR/DRS/2001.10 (http://www.who.int/emc-documents/antimicrobial_resistance/whocdscsrdrs200110.html) accessed 20 December 2001.

6 White NJ. Antimalarial drug resistance and combination chemotherapy Proc. Roy. Soc. London, Ser. B, 1999; 354: 739-749.

7 World Health Organization Fixed-dose Combination Tablets for the treatment of tuberculosis 1999, WHO/CDS/CPC/TB/99.267.

8 Bloland PB., Ettling M., Meek M. Combination therapy for malaria in Africa: hype or hope? Bull. World Health Organization, 2000; 78; 1378-1388.

9 Bloland PB. Drug Resistance in Malaria World Health Organization, 2001, WHO/CDS/CSR/DRS/2001.4 (http://www.who.int/emc-documents/antimicrobial_resistance/docs/malaria.pdf) accessed 10 January 2002.

10 Livermore, 2003

11 Sack DA., Lyke C.., McLaughlin, Suwanvanichkij V. Antimicrobial resistance in Shigellosis, cholera and Camplybacteriosis World Health Organization, 2001, WHO/CDS/CSR/DRS/2001.8 (http://www.who.int/emc-documents/antimicrobial_resistance/docs/whocdscsrdrs20018.htm) accessed 10 January 2002.

12 Perelson AS., Neumann AU., Markowitz M., Leonard JM., Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell number and viral generation time Science, 1966; 271: 1582-1586 (HIV-1 may produce up to 10 billion copies of itself per day). See also Ho DD., Neumann AU., Perelson AS., Chen W., Leonard JM., Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature, 1995; 375: 123-139.

13 Raynaud C., Laneelle MA., Senaratne RH., Draper P., Laneelle G., Daffe M., Microbiology. 1999, Mechanisms of pyrazinamide resistance in mycobacteria: importance of lack of uptake in addition to lack of pyrazinamidase activity.

14 Amalio Telenti, Paul Imboden, Francine Marchesi, Douglas Lowrie, Stewart Cole, Jo Colston, Lukas Matter, Kurt Schopfer, and Thomas Bodmer, 1993 Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis Lancet, 341:647-50.

15 Douglas J. and Steyn L., 1993, A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates J. Infect. Dis. 167:1505-1506.

16 Stephen H., Gillespie, 2002. Minireview: Evolution of Drug Resistance in Mycobacterium tuberculosis: Clinical and Molecular Perspective, Antimicrobial Agents & Chemother. 46: 267-274; Nachega J. & Chaisson RE., 2003 Tuberculosis Drug Resistance: A Global Threat Clin. Infect. Dis. 36(S 1): S24-30.

17 Mberu EK., Mosobo MK., Nzila AM., Kokwaro GO., Sibley CH. et al The changing in vitro susceptibility pattern to pyrethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi Kenya, Am. J. Trop. Med. Hyg, 2000, 62: 396-401.

18 Babett Schwöbel, Michael Alifrangis, Ali Salanti and Tomas Jelinek, 2002 Different mutation patterns of atovaquone resistance to Plasmodium falciparum in vitro and in vivo: rapid detection of codon 268 polymorphisms in the cytochrome b as potential in vivo resistance marker Malaria Journal, 2003, 2:5 (http://www.malariajournal.com/content/2/1/5)..

19 Nzila AM., Mberu EK., Sulo J., Dayo H., Winstanley PA., Sibley CH., Watkins WM., 2002 Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites Antimicrob Agents Chemother, 44:991-6.

20 Schrag SJ., Beall B., Dowell S. Persistent pneumococcal infections World Health Organization, 2001WHO/CDS/CSR/DRS/2001.6 (http://www.who.int/emc-documents/antimicrobial_resistance/docs/whocdscsrdrs20016.htm) accessed 2 December 2001.

21 Jordan R., Gold L., Cummins C., Hyde C., 2002 Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy BMJ 324:757-760

22 Bryceson A., reference 23, below, citing Ellard GA. Rationale of the multidrug regimens recommended by a WHO study group on chemotherapy of leprosy for control programmes, Intl J. Leprosy 1984; 52: 394-401.

23 Bryceson A. A policy for leishmaniasis with respect to the prevention and control of drug resistance Trop. Med. & Intl. Health, 2001; 6: 928-934.

24 White NJ., Nosten F., Looareesuwan S., Watkins WM., Marsh K et al Averting a malaria disaster The Lancet 1999, 353: 1965-1967.

25 Basco L. and Ringwald P., 2002 Drug-resistant malaria: problems with its definition and technical approaches Sante, 10(1):47-50.

26 Bjorkman A., 2002 Malaria associated anaemia, drug resistance and antimalarial combination therapy International Journal for Parasitology 32: 1637-1643.

27 von Seidlein L., Milligan P., Pinder M., Bojang K., Anyalebechi C., Gosling R., Coleman R., Ude JI., Sadiq A., Duraisingh M., Warhurst D., Alloueche A., Targett G., McAdam K., Greenwood B., Walraven G., Olliaro P., Doherty T., 2000 Efficacy of artesunate plus pyrimethamine-sulphadoxine for uncomplicated malaria in Gambian children: a double-blind, randomised, controlled trial Lancet 355, 352-7.

28 Adjuik M., Agnamey P., Babiker A., Borrmann S., Brasseur P., Cisse M., Cobelens F., Diallo S., Faucher JF., Garner, P., Gikunda S., Kremsner PG., Krishna S., Lell B., Loolpapit M., Matsiegui PB., Missinou MA., Mwanza J., Ntoumi F., Olliaro P., Osimbo P., Rezbach P., Some E., Taylor W.R., 2002 Amodiaquine-artesunateversus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial Lancet 359, 1365-72.

29 Susan W. Cox, Jan Albert, Ewa Ljungdahl-Ståhle and Britta Wahren, 1993 Effect of resistance on combination chemotherapy for human immunodeficiency virus infection, Advances in Enzyme Regulation Volume 33 Pages 27-36, available online 21 November 2002.

30 GlaxoSmithKline Trizivir Product Information, August 2001, (http://us.gsk.com/products/assets/us_trizivir.pdf) accessed 3/7/02.

31 Urquhart J. 2001 New Insight into Patient Compliance with Prescribed Drug Regimens Clinical Researcher 1: 26-32 and references cited therein (http://www.aprex.bigstep.com/PDFfiles/ClinicalResearch.pdf) accessed 14 January 2001.

32 Han-Yao Huang, Maureen G. Maguire, Edgar R. Miller, III and Lawrence J., Appelm 2000 Impact of Pill Organizers and Blister Packs on Adherence to Pill Taking in Two Vitamin Supplementation Trials American Journal of Epidemiology, Vol. 152, No. 8: 780-787.

33 Wong BS., Norman DC., 1987 Evaluation of a novel medication aid, the calendar blister-pack, and its effect on drug compliance in a geriatric outpatient clinic J Am Geriatr Soc35:21-6.

34 Ware GJ., Holford NH., Davison JG. et al. 1991 Unit dose calendar packaging and elderly patient compliance N Z Med J 104:495-7.

35 Qingjun L., Jihui D., Laiyi T., Xiangjun Z., Jun L., Hay A., Shires S., Navaratnam V., 1998 The effect of drug packaging on patients compliance with treatment for Plasmodium vivax malaria in China Bull World Health Organ, 76 Suppl 1:21-7.

36 Shwe T., Lwin M., Aung S., 1998 Influence of blister packaging on the efficacy of artesunate + mefloquine over artesunate alone in community-based treatment of non-severe falciparum malaria in Myanmar Bull World Health Organ. 76 Suppl 1:35-41.

37 Pena C., Pujol M., Ardanuy C. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended spectrum beta lactamases Antimicrob. Agents Chemother. 1998; 42: 53-58.

38 Seppala H., Kaukka T., Vuopio-Varkila Muotiala A. et al The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland New Engl. J. Med. 1997; 337: 441-446.

39 Talisuna AO., Kyosiimire-Lugemwa J., Langi P., Mutabingwa TK., Watkins W., Van Marck E., Egwang T., D Alessandro U., 2002 Role of the pfcrt codon 76 mutation as a molecular marker for population-based surveillance of chloroquine (CQ)-resistant Plasmodium falciparum malaria in Ugandan sentinel sites with high CQ resistance Trans R Soc Trop Med Hyg. 96(5):551-6.

40 Nzila AM., Mberu EK., Sulo J., Dayo H., Winstanley PA., Sibley CH., Watkins WM., 2000 Towards an understanding of the mechanism of pyrimethanmine-sulfadoxine resistance in Plasmodium falciparum: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites Antimicrob. Agents Chemother, 44:991-6.

41 Price RN., Price C., Cassar C., Brockman A., Duraisingh M., Van Vugt M., White NJ., Nosten F., Krishna S., 1999 The pfmdr1 Gene Is Associated with a Multidrug-Resistant Phenotype in Plasmodium falciparum from the Western Border of Thailand, Antimicrob. Agents and Chemother, 43: 2943-2949.

42 Mberu EK., Mosobo MK., Nzila AM., Kokwaro GO., Sibley CH., Watkins WM., 2000 The changing in vitro susceptibility pattern to pyrimethamine/sulfadoxine in Plasmodium falciparum field isolates from Kilifi, Kenya Am J Trop Med Hyg. 62(3):396-401.

43 Roper C., Pearce R., Bredenkamp B., Gumede J., Drakeley C., Mosha F., Chandramohan D., Sharp B., 2003 Antifolate antimalarial resistance in southeast Africa: a population-based analysis Lancet. 361:1174-81.

44 Nosten F. et al., 2000 Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study Lancet, 356:297-302.

45 Peters W. and Robinson BL., 1984 The chemiotherapy of rodent malaria XXXV: Further studies on the retardation of drug resistance by the use of a triple combination of mefloquine, pyrimethamine and sulfadoxine in mice infected with P. berghei and P. berghei NS. 1984, Ann. Trop. Med. Parasitol., 78:459-466.